

Kinetic modelling of autoimmune diseases

M.P. Ramos, **A.J. Soares**, C. Ribeiro

Centre of Mathematics
University of Minho, Portugal



Universidade do Minho

Escola de Ciências

Centro de Matemática

Recent advances in kinetic equations and applications

2019 November 11-15

Structure of the talk

1. Introduction

Motivation & biological considerations

Autoimmune diseases

2. The model for autoimmunity

Cellular interactions

Kinetic equations

Macroscopic equations

3. Qualitative analysis

Existence and uniqueness result

Positivity and asymptotic behaviour of the solution

4. Numerical tests

Results & biological interpretation

Motivation

Normally, the immune system

- **identifies** the difference between foreign cells and our own cells;
- **protects against** germs, like bacteria and viruses;
- **recognizes foreign invaders** and sends out cells to attack them.

An **autoimmune disease** is a condition in which our immune system **wrongly** attacks our own cells.

In many cases, it is **chronic**, and patients alternate periods of **relapse** having **suffering** symptoms, with periods of **remittance** in which symptoms are **absent**.

Our objective

To construct a mathematical model of **kinetic type** in order to describe the **immune system interactions** in the context of **autoimmune disease**.

State of the art

It is well known that the immune system can be regarded, at the cellular level, as a system constituted by a large number of cells, belonging to **several interacting populations**.

Cellular interactions can modify the behaviour or **activity** of cells and can also modify the **size** of populations.

The behaviour can be modelled within a **kinetic theory** approach in terms of the statistical distribution of all states possessed by each cell population.

State of the art

After the pioneering work

Jager & Segel (1992), for population of social organisms,

Kinetic modelling approaches have been used to describe **tumor-immune system interactions** and **immune competition**

Bellomo & Forni (1994)

Arlotti & Bellomo (1995)

Arlotti & Lachowicz & Latrach (1996)

Arlotti & Bellomo & Latrach (1999)

Delitala (2002)

Kolev (2003, 2005)

Kolev & Nikolova (2007)

Angelis & Lods (2008)

Bellouquid & Angelis (2011)

Conte & Groppi & Spiga (2018)

Cell populations

We consider three interacting populations in the autoimmune competition


(SAPCs) Self Antigen Presenting Cells (A)

(SRTCs) Self Reactive T cells (R)

(ISCs) Immunosuppressive Cells (S)

SRTCs are activated when they encounter a **SAPC** that has digested a self-antigen.

(ISCs) regulate the activity of **SRTCs** and **SAPCs**.



Assumptions

- Only **binary interactions** between cells are significant.
- Interactions are **instantaneous** and homogeneous in space.
- The functional state of each population is described by the **biological activity** variable, $u \in [0, 1]$;
- Interactions can be **conservative**, **proliferative** and **destructive**.

Cellular activity

The behaviour of cells is described by **distribution functions**

$$f_i: [0, \infty] \times [0, 1] \rightarrow \mathbb{R}^+, \quad i = 1, 2, 3$$

and the expected number of cells of the i -population at time t is given by

$$n_i(t) = \int_0^1 f_i(t, u) \, du, \quad i = 1, 2, 3. \quad (1)$$

Cellular activity (meaning)


(SAPCs) Self Antigen Presenting Cells

their activity u is the ability to stimulate and activate SRTCs

$u=0$ means that

the simulation by SAPCs does not activate SRTCs

does not induce an autoimmune response



Cell activity


(SRTCs) Self Reactive T cells

their activity u is the secretion of cytokines

$u = 0$ means that the SRTCs do not produce cytokines

SRTCs are tolerant to SAPCs


no inflammatory process is triggered



Cell activity

(ISCs) Immunosuppressive Cells

their activity u is the ability to inhibit the autoimmune response
suppressing the activity of SAPCs and SRTCs
or eliminating SAPCs and SRTCs



Kinetic equations

$$\frac{\partial f_i}{\partial t}(t, u) = G_i[f](t, u) - L_i[f](t, u) + S_i[f](t, u), \quad i = 1, 2, 3,$$

where

$$f = (f_1, f_2, f_3)$$

and

- $G_i[f](t, u) - L_i[f](t, u)$ corresponds to conservative interactions
- $S_i[f](t, u)$ corresponds to proliferative or destructive interactions

The cellular interaction terms have the **structure**

$$G_i[f](t, u) = \sum_{j=1}^3 \int_0^1 \int_0^1 \eta_{ij}(v, w) \psi_{ij}(v, w; u) f_i(t, v) f_j(t, w) dv dw$$

$$L_i[f](t, u) = f_i(t, u) \sum_{j=1}^3 \int_0^1 \eta_{ij}(u, v) f_j(t, v) dv$$

$$S_i[f](t, u) = f_i(t, u) \sum_{j=1}^3 \int_0^1 s_{ij}(u, v) f_j(t, v) dv$$

where

$\eta_{ij}(v, w) \geq 0$ is the **encounter rate** of a conservative interaction

$s_{ij}(u, v)$ is the **proliferation** or **destruction rate**

$\psi_{ij}(v, w; u) \geq 0$ is the **transition probability density**

and satisfies

$$\int_0^1 \psi_{ij}(v, w; u) du = 1, \quad i, j = 1, 2, 3, \quad v, w \in [0, 1]$$

Cellular interactions (from biological considerations)

Conservative interactions

Interactions **SAPCs**–**ISCs** decrease the activity of **SAPCs**

Interactions **SRTCs**–**ISCs** decrease the activity of **SRTCs**

Interactions **SAPCs**–**SRTCs** increase the activity of **SAPCs**
and also that of **SRTCs**

Proliferative interactions

Interactions **SRTCs**–**SAPCs** increase the number of **SRTCs**
and also the number of **SAPCs** (autoimmune cascade)

Interactions **SAPCs**–**ISCs** increase the number of **ISCs**

Destructive interactions

Interactions **ISCs**–**SAPCs** result in the elimination of **SAPCs**

Interactions **ISCs**–**SRTCs** decrease the number of **SRTCs**

Cellular interactions (from biological considerations)

In proliferative interactions, we consider that

the newborn cells inherit the same aggressive state as the mother cells
the proliferation rates are constant

In destructive interactions, we consider that

the destructive rates are constant

For the population of ISCs, we consider that

the distribution function is independent of its functional state

The kinetic equations are given by

Population p_1 of SAPCs

- $$\begin{aligned} \frac{\partial f_1}{\partial t}(t, u) = & 2c_{12} \int_0^u (u - v) f_1(t, v) dv \int_0^1 f_2(t, w) dw \\ & - c_{12} (u - 1)^2 f_1(t, u) \int_0^1 f_2(t, w) dw \\ & + 2c_{13} f_3(t) \int_u^1 (v - u) f_1(t, v) dv - c_{13} u^2 f_1(t, u) f_3(t) \\ & + p_{12} f_1(t, u) \int_0^1 f_2(t, w) dw \\ & - d_{13} f_1(t, u) f_3(t) \end{aligned}$$

Populations p_2 of **SRTCs** and populations p_3 of **ISCs**

- $$\begin{aligned} \frac{\partial f_2}{\partial t}(t, u) = & 2c_{21} \int_0^u (u - v)f_2(t, v)dv \int_{w^*}^1 f_1(t, w)dw \\ & - c_{21}(u - 1)^2 f_2(t, u) \int_0^1 f_1(t, w)dw \\ & + 2c_{23}f_3(t) \int_u^1 (v - u)f_2(t, v)dv - c_{23}u^2 f_2(t, u)f_3(t) \\ & p_{21}f_2(t, u) \int_0^1 f_1(t, w)dw - d_{23}f_2(t, u)f_3(t) \end{aligned}$$
- $$\frac{df_3}{dt}(t) = p_{31}f_3(t) \int_0^1 f_1(t, w)dw$$

w^* is a parameter related to **tolerance** of **SRTCs** to **SAPCs**

For this system, we consider the following initial data

$$f_1(0, u) = f_1^0(u), \quad f_2(0) = f_2^0(u), \quad f_3(0) = f_3^0, \quad \text{with } f_i^0 > 0, \text{ for } i=1, 2, 3.$$

The macroscopic equations

From the **kinetic equations** we formally derive balance equations for the **cellular density of each population**.

Integrating over the biological activity variable, $u \in [0, 1]$, we obtain

$$\dot{n}_1(t) = p_{12}n_1(t)n_2(t) - d_{13}n_1(t)n_3(t)$$

$$\dot{n}_2(t) = p_{21}n_2(t)n_1(t) - d_{23}n_2(t)n_3(t)$$

$$\dot{n}_3(t) = p_{31}n_3(t)n_1(t)$$

As usual, **we loose the effects of conservative interactions**.

For this system, we consider the following initial data

$$n_1(0) = n_1^0, \quad n_2(0) = n_2^0, \quad n_3(0) = n_3^0, \quad \text{with } n_i^0 > 0, \text{ for } i=1, 2, 3.$$

Wellposedness of the IVP (kinetic)

A result of paper [1], for η_{ij} and ψ_{ij} real valued, measurable and uniformly bounded, implies

Theorem 1 (local existence)

Assume initial data $f_i(0)$ in $L^1[0, 1]$.

Then, there exists $T_0 > 0$ such that a unique positive solution to the Cauchy problem for our **kinetic system** exists in $L^1[0, 1]$, for $t \in [0, T_0]$.

[1] L. Arlotti, N. Bellomo, K. Latrach. *Mathl. Comput. Modelling*, **30**, 15–40 (1999).

Kinetic *versus* macro

Thanks to a result of paper [2],

- the **boundedness** of the solution to the **macroscopic** system implies the **boundedness** of the solution to the **kinetic** system
- if the solution to the **macroscopic** system **blows up** then so does the solution to the **kinetic** system

The **basic assumptions** are

- **constant** destruction and proliferation rates
- cloned cells (proliferative encounters) **inherit the** same aggressive state as their mother cells

Therefore, the basic information about our kinetic system can be “extracted” from the corresponding macroscopic equations.

[2] L. Arlotti, M. Lachowicz, *Mathl. Comput. Modelling*, **23**, 11–29 (1996).

Positivity of the existing solution

Theorem 2

If $(n_1(t), n_2(t), n_3(t))$ is a solution to the Cauchy problem for the **macroscopic equations** defined on the time interval $[0, T]$, with $0 < T < \infty$, then this solution is **positive**, that is

$$n_1(t) > 0, \quad n_2(t) > 0, \quad n_3(t) > 0, \quad t \in [0, T].$$

Existence, uniqueness and asymptotic behaviour

Theorem 3

If the proliferative rates p_{21} , p_{31} are such that $p_{21} < p_{31}$, then the **Cauchy problem** for the **macroscopic equations** has a unique global solution $(n_1(t), n_2(t), n_3(t))$ defined on all \mathbb{R}^+ .

This solution is **bounded** and

$$\lim_{t \rightarrow \infty} n_1(t) = 0,$$

$$\lim_{t \rightarrow \infty} n_2(t) = 0,$$

$$\lim_{t \rightarrow \infty} n_3(t) = \alpha < +\infty,$$

whatever are the corresponding initial data.

Numerical tests

Simulations

We **solve** numerically the kinetic system, by **discretizing** the equations in the **activation** variable and using a **quadrature** rule (trapezoidal).

Objective

Investigate the influence of certain parameters on the behaviour of the solution.

Idea

Which **trends** or **reactions** typical in autoimmune diseases can be reproduced by our kinetic model?

Numerical scheme

The discretization of the activation state variable u , combined with quadrature approximations, leads to a system of $2(m+1)+1$ ODEs,


$$\begin{aligned}\frac{df_1^k}{dt}(t) &= 2c_{13}f_3(t) \left(\mathcal{Q}_k^m[vf_1(t, v)] - u_k \mathcal{Q}_k^m[f_1(t, v)] \right) - c_{13}u_k^2 f_1^k(t) f_3(t) \\ &\quad + c_{12} \left[2 \left(u_k \mathcal{Q}_0^k[f_1(t, v)] - \mathcal{Q}_0^k[vf_1(t, v)] \right) - (u_k - 1)^2 f_1^k(t) \right] \mathcal{Q}_0^m[f_2(t, v)] \\ &\quad + p_{12} f_1^k(t) \mathcal{Q}_0^m[f_2(t, v)] - d_{13} f_1^k(t) f_3(t), \quad k = 0, \dots, m, \\ \frac{df_2^k}{dt}(t) &= 2c_{23}f_3(t) \left(\mathcal{Q}_k^m[vf_2(t, v)] - u_k \mathcal{Q}_k^m[f_2(t, v)] \right) - c_{23}u_k^2 f_2^k(t) f_3(t) \\ &\quad + c_{21} \left[2 \left(u_k \mathcal{Q}_0^k[f_2(t, v)] - \mathcal{Q}_0^k[vf_2(t, v)] \right) \mathcal{Q}_\ell^m[f_1(t, v)] - (u_k - 1)^2 f_2^k(t) \mathcal{Q}_0^m[f_1(t, v)] \right] \\ &\quad + p_{21} f_2^k(t) \mathcal{Q}_0^m[f_1(t, v)] - d_{23} f_2^k(t) f_3(t), \quad k = 0, \dots, m, \\ \frac{df_3}{dt}(t) &= p_{31} f_3(t) \mathcal{Q}_0^m[f_1(t, v)].\end{aligned}$$

Numerical tests

Trending to illness

ISCs are unable to regulate the autoimmune reaction.

The result is a full autoimmune cascade and trending to illness.




Mass proliferation of very active SRTCs due to insufficient regulation by ISCs or insufficient destruction of SRTCs and SAPCs by ISCs or low tolerance of SRTCs to self-antigens.

$$p_{12} = 20, p_{21} = 19, p_{31} = 20, \\ d_{13} = 0.35, d_{23} = 0.025, w^* = 1/30.$$

Numerical tests

Immunosuppression

ISCs are efficient in aborting the autoimmune reaction.
The result is the suppression of the autoimmune reaction.



Very low proliferation of active **SRTCs**
due to an efficient regulation by **ISCs**

SAPCs are less efficient in increasing the
activity of **SRTCs**


$$p_{12} = 20, p_{21} = 19, p_{31} = 22,$$
$$d_{13} = 0.35, d_{23} = 0.025, w^* = 1/30.$$

Numerical tests

Immunotolerance

SRTCs become more tolerant to **SAPC**s

The result is a lowering effect on the number of **SRTC**s with high activity



Very low proliferation of active **SRTC**s

SRTCs become more tolerant to **SAPC**s

$$p_{12} = 20, p_{21} = 19, p_{31} = 20,$$

$$d_{13} = 0.35, d_{23} = 0.025, w^* = 5/6.$$

Perspectives

Work in progress

- An **immunotherapy treatment** was introduced in the description
- A **fourth population** of Interleukin-2 (IL-2) is considered to induce the proliferation of **ISCs**
- An artificial inlet representing an **external drug therapy** is introduced

Future work

- Other biological relevant populations can be introduced in the model
- A time delay can be included in the model to describe the **chronicity** of the autoimmune disease.

Thank you for your attention!